Bristol-Myers Squibb (NY:BMY)

58.81 -2.34 (-3.83%)

Official Closing Price Updated: 4:10 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

93 94 Next >

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗

January 09, 2025

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Via Benzinga

January 09, 2025

Via The Motley Fool

Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators ↗

January 08, 2025

Alger launched its INVN ETF, with holdings including BioMarin, Teradata, and Bristol-Myers Squibb.

Via Benzinga

Topics ETFs

Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

January 08, 2025

Via Benzinga

3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade ↗

January 04, 2025

Via The Motley Fool

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? ↗

December 31, 2024

Via Benzinga

Peering Into Bristol-Myers Squibb's Recent Short Interest ↗

December 31, 2024

Via Benzinga

2 High-Yield Dividend Stocks to Buy Early in 2025 ↗

December 31, 2024

Via The Motley Fool

Deal Dispatch: Vera Bradley Is A Mixed Bag, Modell's Ex-CEO Explores Party City ↗

January 03, 2025

Vera Bradley faces shareholder pressure for underperformance, while acquisitions and restructurings define this week's deal landscape.

Via Benzinga

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

January 03, 2025

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

December 27, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Stock Earns 83 RS Rating ↗

December 19, 2024

On Thursday, Bristol Myers Squibb stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83.

Via Investor's Business Daily

Exploring BRISTOL-MYERS SQUIBB CO's Technical Signals and Breakout Potential. ↗

December 27, 2024

Investors are keeping a close eye on BRISTOL-MYERS SQUIBB CO (NYSE:BMY) as it boasts an impressive technical rating of 7 out of 10, signaling a possible breakout.

Via Chartmill

Schwab US Dividend Equity ETF Reverses In December: What's Going On? ↗

December 23, 2024

The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund:

Via Benzinga

Topics ETFs

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

December 23, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

December 23, 2024

From Bristol Myers Squibb

Via Business Wire

Got $500? This Top Dividend ETF Is a Great Buy After Its Recent Sell-Off. ↗

December 23, 2024

Via The Motley Fool

Topics ETFs

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗

December 22, 2024

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.

Via Benzinga

Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 21 ↗

December 21, 2024

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 16-20, 2024.

Via Talk Markets

Topics Stocks / Equities

Want Decades of Passive Income? 3 Stocks to Buy Right Now ↗

December 21, 2024

Passive income requires solid companies and a solid underlying industry. Here are some top names that fit both bills.

Via The Motley Fool

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services ↗

December 19, 2024

U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.

Via Benzinga

3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income ↗

December 19, 2024

Via The Motley Fool

Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025

December 19, 2024

From Bristol Myers Squibb

Via Business Wire

Got $250? 2 Healthcare Stocks to Buy and Hold Forever ↗

December 19, 2024

Via The Motley Fool

These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy? ↗

December 19, 2024

Via The Motley Fool

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

December 18, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy ↗

December 18, 2024

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.

Via Investor's Business Daily

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

December 18, 2024

From FN Media Group LLC

Via GlobeNewswire

Sanofi's 340B Credit Proposal Draws Federal Warning For Statutory Violation ↗

December 17, 2024

HRSA warns Sanofi that its credit model for 340B drugs violates the statute, demanding immediate cessation to avoid penalties and pricing agreement termination.

Via Benzinga

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields ↗

December 17, 2024

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

93 94 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.